# US 2012/0269824 A1 · Therapeutic human anti-il-1r1 monoclonal antibody

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0269824 A1
- Document ID: US20120269824A1
- Status: Published application
- Kind: A1
- Application number: 13/450,126
- Filed: 2012-04-18
- Published: 2012-10-25
- Earliest claimed: 2002-09-06
- Assignees: Medarex, Inc.; Amgen Inc.
- Inventors: Brian Varnum; Chris Vezina; Alison Witte; Xueming Qian; Francis Hall Martin; Haichun Huang; Gary Elliott
- Web page: https://patentgrep.com/patent/US20120269824A1

## CPC

- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/12: Antidiarrhoeals
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/02: Nutrients, e.g. vitamins, minerals
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/50: for increasing or potentiating the activity of insulin
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 7/08: Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock (artificial tears A61P27/04)
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 13/10: of the bladder
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/06: Antiabortive agents; Labour repressants
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/04: for non-specific disorders of the connective tissue
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 23/02: Local anaesthetics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/06: Antimigraine agents
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.

## Claims

### Claim at position 1

1-61. (canceled)

### Claim 62

An isolated antibody or antigen binding fragment thereof that specifically binds human interleukin-1 receptor type 1 (IL-1R1), comprising:
(a) a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region comprising SEQ ID NO: 84, or the antigen binding fragment thereof, and the light chain comprises a light chain variable region comprising SEQ ID NO: 83, or the antigen binding fragment thereof, wherein the antigen binding fragment of the heavy chain variable region comprises an N-terminal or C-terminal deletion of SEQ ID NO: 84 comprising at least SEQ ID NO: 61, SEQ ID NO:64, and SEQ ID NO: 67, and the antigen binding fragment of the light chain variable region comprises an N-terminal or C-terminal deletion of SEQ ID NO: 83 comprising at least SEQ ID NO: 70, SEQ ID NO: 72, and SEQ ID NO: 74; or
(b) a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region comprising SEQ ID NO: 82, or the antigen binding fragment thereof, and the light chain comprises a light chain variable region comprising SEQ ID NO: 83, or the antigen binding fragment thereof, wherein the antigen binding fragment of the heavy chain variable region comprises an N-terminal or C-terminal deletion of SEQ ID NO: 82 comprising at least SEQ ID NO: 62, SEQ ID NO:65, and SEQ ID NO: 68, and the antigen binding fragment of the light chain variable region comprises an N-terminal or C-terminal deletion of SEQ ID NO: 83 comprising at least SEQ ID NO: 70, SEQ ID NO: 72, and SEQ ID NO: 74.

### Claim 63

An isolated antibody or antigen binding fragment thereof comprising:
(a) a human heavy chain comprising human heavy chain framework regions, a human heavy chain CDR1 region comprising SEQ ID NO: 61, a human heavy chain CDR2 region comprising SEQ ID NO: 64, and a human heavy chain CDR3 region comprising SEQ ID NO: 67; and a human light chain comprising human light chain framework regions, a human light chain CDR1 region comprising SEQ ID NO: 70, a human light chain CDR2 region comprising SEQ ID NO: 72, and a human light chain CDR3 region comprising SEQ ID NO: 74; or
(b) a human heavy chain comprising human heavy chain framework regions, a human heavy chain CDR1 region comprising SEQ ID NO: 62, a human heavy chain CDR2 region comprising SEQ ID NO: 65, and a human heavy chain CDR3 region comprising SEQ ID NO: 68; and a human light chain comprising human light chain framework regions, a human light chain CDR1 region comprising SEQ ID NO: 70, a human light chain CDR2 region comprising SEQ ID NO: 72, and a human light chain CDR3 region comprising SEQ ID NO: 74.

### Claim 64 (depends on 63)

The antibody or antigen binding fragment of claim 63, which is an antigen binding fragment, wherein the heavy chain and light chain of the antigen binding fragment are connected by a flexible linker to form a single-chain antibody.

### Claim 65 (depends on 64)

The antibody or antigen binding fragment of claim 64, which antigen binding fragment is a single-chain Fv antibody.

### Claim 66 (depends on 63)

The antibody or antigen binding fragment of claim 63, which is a Fab antibody fragment.

### Claim 67 (depends on 63)

The antibody or antigen binding fragment of claim 63, which is Fab′ antibody fragment.

### Claim 68 (depends on 63)

The antibody or antigen binding fragment of claim 63, which is a (Fab′)2 antibody fragment.

### Claim 69 (depends on 63)

The antibody or antigen binding fragment thereof of claim 63, which is a fully human antibody or antigen binding fragment.

### Claim 70 (depends on 63)

The antibody or antigen binding fragment thereof of claim 63, wherein the antibody, or antigen binding fragment thereof, inhibits binding of IL-1 to human IL-1R1 receptor.

### Claim 71 (depends on 63)

The antibody or antigen binding fragment thereof of claim 63, which is an IgG2 antibody or antigen binding fragment.

### Claim 72 (depends on 63)

The antibody or antigen binding fragment thereof of claim 63, which binds specifically to the amino acid sequence of SEQ ID NO: 76.

### Claim 73 (depends on 63)

The antibody or antigen binding fragment thereof of claim 63, wherein the antibody or antigen binding fragment thereof binds specifically to a portion of the amino acid sequence of human IL-1R1, wherein the portion of the amino acid sequence to which the antibody specifically binds comprises the amino acid sequence YSV.

### Claim 74 (depends on 63)

A composition comprising a pharmaceutically acceptable carrier, excipient or diluent, and the antibody or antigen binding fragment thereof of claim 63.

### Claim 75

An isolated antibody or an antigen binding fragment thereof that specifically binds human interleukin-1 receptor type 1 (IL-1R1), comprising:
(a) a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region comprising SEQ ID NO: 84; or
(b) a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region comprising SEQ ID NO: 82; or
(c) a heavy chain and a light chain, wherein the light chain comprises a light chain variable region comprising SEQ ID NO: 83.
